New England Cancer Specialists

Scarborough, ME
(831) 888-0898

Accepting patients

CARE Study

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

NCI-COG Pediatric MATCH

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Learn more
  • ALK Inhibitor
  • EphA2 Inhibitor
  • Phase 2
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

TAPUR

Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Learn more
  • ROS1 Inhibitor
  • Phase 2